Oral News and Research

RSS

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.

26 Oct 2010

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced positive results from a Phase I/II challenge study of its norovirus virus-like particle (VLP) vaccine candidate.

26 Oct 2010

Fluoride consumption can cause mild enamel fluorosis

Young children who consume substantial amounts of fluoride through infant formula and other beverages mixed with fluoridated water or by swallowing fluoride toothpaste have an increased chance of developing mild enamel fluorosis, according to research published in the October issue of The Journal of the American Dental Association and supported by the National Institute of Dental and Craniofacial Research.

26 Oct 2010

B-complex vitamins slow down mild cognitive impairment

Large doses of B-complex vitamins could reduce the rate of brain shrinkage by half in elderly people with memory problems and slow the progression of dementia.

25 Oct 2010

World Vision increases response in cholera affected Haiti

As the cholera outbreak continues to spread in the Artibonite region of Haiti, World Vision is increasing its response in affected areas, pre-positioning much-needed health supplies and preparing residents in its displacement camps in Port-au-Prince with critical, life-saving health and hygiene messages.

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting.

25 Oct 2010

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Emisphere Technologies, Inc. announced today that Novartis Pharma AG provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021).

25 Oct 2010

Botox beneficial for cosmetic dental treatment

A significant majority of dental implant patients are older with facial aging and their dentists may need to consider the benefits of rejuvenation techniques, such as Botox, for maximizing the cosmetic outcomes of the procedure, according to a leading cosmetic surgeon speaking at the American Academy of Implant Dentistry annual meeting.

25 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

FDA approves LO LOESTRIN FE tablets for oral contraception

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy.

25 Oct 2010

Medivir reports consolidated net sales of SEK 54.7M

Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

22 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

PSST training helps mothers to cope with stress associated with child's disease

Mothers who have children diagnosed with cancer now have a better approach to address and cope with stresses associated with their child's disease. A new certified intervention has proven to be more effective long term compared to other psychological methods, as reported today at the 42nd Congress of the International Society of Pediatric Oncology.

22 Oct 2010

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).

22 Oct 2010

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Oral cancer linked to oral sex: Study

Swedish researchers have found that the Human papillomavirus (HPV) that causes cervical cancer in women is also a risk factor for oropharyngeal squamous cell carcinoma (OSCC) or oral and throat cancer in men even if they do not smoke or consume alcohol.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Scientists and engineers from around the world will gather on the shores of Lake Ontario in Rochester, N.Y. next week to discuss some of the latest breakthroughs in lasers and optics and their applications to cutting-edge science, the development of new materials, and medicine.

21 Oct 2010

$OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS$

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.

21 Oct 2010

Oral News and Research

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

Fluoride consumption can cause mild enamel fluorosis

B-complex vitamins slow down mild cognitive impairment

World Vision increases response in cholera affected Haiti

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Botox beneficial for cosmetic dental treatment

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

FDA approves LO LOESTRIN FE tablets for oral contraception

Medivir reports consolidated net sales of SEK 54.7M

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

PSST training helps mothers to cope with stress associated with child's disease

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Oral cancer linked to oral sex: Study

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News